Abstract

Despite the clear major contribution of hyperlipidemia to the prevalence of cardiovascular disease in the developed world, the direct effects of lipoproteins on endothelial cells have remained obscure and are under debate. Here we report a previously uncharacterized mechanism of vessel growth modulation by lipoprotein availability. Using a genetic screen for vascular defects in zebrafish, we initially identified a mutation, stalactite (stl), in the gene encoding microsomal triglyceride transfer protein (mtp), which is involved in the biosynthesis of apolipoprotein B (ApoB)-containing lipoproteins. By manipulating lipoprotein concentrations in zebrafish, we found that ApoB negatively regulates angiogenesis and that it is the ApoB protein particle, rather than lipid moieties within ApoB-containing lipoproteins, that is primarily responsible for this effect. Mechanistically, we identified downregulation of vascular endothelial growth factor receptor 1 (VEGFR1), which acts as a decoy receptor for VEGF, as a key mediator of the endothelial response to lipoproteins, and we observed VEGFR1 downregulation in hyperlipidemic mice. These findings may open new avenues for the treatment of lipoprotein-related vascular disorders.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Live imaging of lymphatic development in the zebrafish. Nat. Med. 12, 711–716 (2006).

  2. 2.

    & In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 248, 307–318 (2002).

  3. 3.

    et al. Microsomal triglyceride transfer protein in plasma and cellular lipid metabolism. Curr. Opin. Lipidol. 19, 277–284 (2008).

  4. 4.

    et al. Knockout of the abetalipoproteinemia gene in mice: reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes. Proc. Natl. Acad. Sci. USA 95, 8686–8691 (1998).

  5. 5.

    et al. Developmental expression and nutritional regulation of a zebrafish gene homologous to mammalian microsomal triglyceride transfer protein large subunit. Dev. Dyn. 232, 506–518 (2005).

  6. 6.

    & Microsomal triglyceride transfer protein is required for yolk lipid utilization and absorption of dietary lipids in zebrafish larvae. Biochemistry 45, 15179–15187 (2006).

  7. 7.

    et al. Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circ. Res. 104, 952–960 (2009).

  8. 8.

    & Lessons from “lower” organisms: what worms, flies, and zebrafish can teach us about human energy metabolism. PLoS Genet. 3, e199 (2007).

  9. 9.

    , , & Microsomal triglyceride transfer protein expression during mouse development. J. Lipid Res. 41, 532–537 (2000).

  10. 10.

    & The evolution of plasma cholesterol: direct utility or a “spandrel” of hepatic lipid metabolism? Prog. Lipid Res. 48, 73–91 (2009).

  11. 11.

    et al. Both apolipoprotein E and A-I genes are present in a nonmammalian vertebrate and are highly expressed during embryonic development. Proc. Natl. Acad. Sci. USA 94, 8622–8627 (1997).

  12. 12.

    , , , & Germ cell migration in zebrafish is dependent on HMGCoA reductase activity and prenylation. Dev. Cell 6, 295–302 (2004).

  13. 13.

    & The T box transcription factor no tail in ciliated cells controls zebrafish left-right asymmetry. Curr. Biol. 14, 685–690 (2004).

  14. 14.

    , , & The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu. Rev. Nutr. 20, 663–697 (2000).

  15. 15.

    et al. Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum. Mol. Genet. 2, 2109–2116 (1993).

  16. 16.

    & Abetalipoproteinemia. New insights into lipoprotein assembly and vitamin E metabolism from a rare genetic disease. J. Am. Med. Assoc. 270, 865–869 (1993).

  17. 17.

    et al. Genetic analysis of digestive physiology using fluorescent phospholipid reporters. Science 292, 1385–1388 (2001).

  18. 18.

    et al. Genome-wide reverse genetics framework to identify novel functions of the vertebrate secretome. PLoS ONE 1, e104 (2006).

  19. 19.

    , & Zebrafish lipid metabolism: from mediating early patterning to the metabolism of dietary fat and cholesterol. Methods Cell Biol. 101, 111–141 (2011).

  20. 20.

    Apolipoprotein C–II deficiency. Adv. Exp. Med. Biol. 201, 211–226 (1986).

  21. 21.

    et al. An apolipoprotein CII mutation, CIILys19—Thr' identified in patients with hyperlipidemia. Dis. Markers 9, 73–80 (1991).

  22. 22.

    et al. Familial homozygous hypercholesterolemia: report of two patients and review of the literature. Pediatr. Dermatol. 24, 230–234 (2007).

  23. 23.

    Plasma lipoproteins: genetic influences and clinical implications. Nat. Rev. Genet. 10, 109–121 (2009).

  24. 24.

    , & Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease. J. Clin. Invest. 80, 1597–1606 (1987).

  25. 25.

    , & Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin. Thromb. Hemost. 26, 529–537 (2000).

  26. 26.

    Hypercholesterolemia and angiogenesis. Am. J. Cardiol. 72, 61C–64C (1993).

  27. 27.

    & Mouse models of hyperlipidemia and atherosclerosis. Front. Biosci. 6, D515–D525 (2001).

  28. 28.

    , , , & Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified Apoe and Ldlr mice. Clin. Chem. Lab. Med. 43, 470–479 (2005).

  29. 29.

    , , , & Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA 95, 9349–9354 (1998).

  30. 30.

    et al. Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Blood 99, 2397–2407 (2002).

  31. 31.

    , , & Local guidance of emerging vessel sprouts requires soluble Flt-1. Dev. Cell 17, 377–386 (2009).

  32. 32.

    et al. Arteries provide essential guidance cues for lymphatic endothelial cells in the zebrafish trunk. Development 137, 2653–2657 (2010).

  33. 33.

    , , , & Identification of the lipoprotein initiating domain of apolipoprotein B. J. Biol. Chem. 278, 44702–44707 (2003).

  34. 34.

    , & LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 32, 213–229 (1979).

  35. 35.

    , , & Ligand-independent activation of vascular endothelial growth factor receptor 1 by low-density lipoprotein. EMBO Rep. 8, 1155–1161 (2007).

  36. 36.

    & On the relationship of LDL and VEGFR1: not just a family affair. EMBO Rep. 8, 1127–1128 (2007).

  37. 37.

    et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α. Nature 451, 1008–1012 (2008).

  38. 38.

    , & Hungry for blood vessels: linking metabolism and angiogenesis. Dev. Cell 14, 313–314 (2008).

  39. 39.

    et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464, 917–921 (2010).

  40. 40.

    , , , & Angiogenic network formation in the developing vertebrate trunk. Development 130, 5281–5290 (2003).

  41. 41.

    et al. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development 129, 3009–3019 (2002).

  42. 42.

    , & The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev. Biol. 230, 278–301 (2001).

  43. 43.

    , & Solubilization of apolipoprotein B and its specific binding by the cellular receptor for low density lipoprotein. Proc. Natl. Acad. Sci. USA 74, 5150–5154 (1977).

  44. 44.

    , & Fibroblast growth factor 2–induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. J. Cell. Mol. Med. 13, 2061–2068 (2009).

  45. 45.

    , , , & Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis. Curr. Biol. 12, 1405–1412 (2002).

  46. 46.

    & A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911–917 (1959).

  47. 47.

    et al. GLYCOALKALOID METABOLISM1 is required for steroidal alkaloid glycosylation and prevention of phytotoxicity in tomato. Plant Cell 23, 4507–4525 (2011).

  48. 48.

    et al. Combinatorial function of ETS transcription factors in the developing vasculature. Dev. Biol. 303, 772–783 (2007).

  49. 49.

    & Identification of genes expressed by zebrafish oligodendrocytes using a differential microarray screen. Dev. Dyn. 239, 2041–2047 (2010).

  50. 50.

    et al. Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. Dev. Cell 21, 301–314 (2011).

  51. 51.

    , & Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119, 203–210 (1989).

  52. 52.

    , , , & A Drosophila microsomal triglyceride transfer protein homolog promotes the assembly and secretion of human apolipoprotein B. Implications for human and insect transport and metabolism. J. Biol. Chem. 278, 20367–20373 (2003).

  53. 53.

    , , , & Combinatorial interaction between CCM pathway genes precipitates hemorrhagic stroke. Dis. Model Mech. 1, 275–281 (2008).

Download references

Acknowledgements

The authors would like to thank G. Palardy, R. Miyares, N. Nevo, I. Harel, T. Berkutzki, I. Raviv, R. Oren and C. Rot for technical assistance; A. Aharoni for help with GC-MS analyses; E. Zelzer (Weizmann Institute, Israel) for providing the Ldlr-null mice, K. Tordjman (Sourasky Medical Center, Israel) for providing the ApoE-null mice, S. Schulte-Merker (Hubrecht Institute) for providing the vegfr1 plasmid and the Tg(flt1:YFP)hu4624 transgenic line; J. Berliner (University of California Los Angeles, California) for providing human aortic endothelial cells (HAECs); D. Haratz, I. Groskop and A. Shaish for advice regarding lipid analyses; A. Harmelin and N. Stettner for animal care; and I.B. Dawid, E. Tzahor, A. Gross, B. Shilo and J. Torres-Vazquez for critical reading of the manuscript. The authors are grateful to all the members of the Yaniv and Weinstein labs for discussion, technical assistance and continuous support. This work was supported in part by Israel Science Foundation 748/2009 (to K.Y.), Marie Curie Actions-International Reintegration grants FP7-PEOPLE-2009-RG 256393 (to K.Y.), the Yeda-Sela Center (to K.Y.), the Israel Cancer Research Foundation Postdoctoral Fellowship (to I.A.-D.), US National Institutes of Health (NIH) RO1CA126935 (to M.L.I.-A.), NIH T32HL069766 (training grant for T.T.C. and C.M.W.) and NIH HL049373 (to G.S.S.). S.A.F. is funded by the NIH (R56DK093399 and R01GM063904), the Carnegie Institution for Science endowment and the G. Harold and Leila Y. Mathers Charitable Foundation. B.M.W. is supported by the intramural program of the National Institute of Child Health and Human Development, NIH, and by the Foundation Leducq.

Author information

Author notes

    • Josette Ungos
    • , Kameha Kidd
    •  & Kenna Shaw

    These authors contributed equally to this work.

Affiliations

  1. Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.

    • Inbal Avraham-Davidi
    • , Yona Ely
    • , Moshe Grunspan
    • , Guy Malkinson
    • , Liron Gibbs-Bar
    • , Oded Mayseless
    • , Gabriella Allmog
    •  & Karina Yaniv
  2. Laboratory of Molecular Genetics, National Institute of Child Health and Human Development, US National Institutes of Health (NIH), Bethesda, Maryland, USA.

    • Van N Pham
    • , Daniel Castranova
    • , Brigid Lo
    • , Josette Ungos
    • , Kameha Kidd
    • , Kenna Shaw
    •  & Brant M Weinstein
  3. Department of Molecular, Cell and Developmental Biology, University of California Los Angeles, Los Angeles, California, USA.

    • Carmen M Warren
    • , Tom T Chen
    •  & M Luisa Iruela-Arispe
  4. Department of Plant Sciences, Weizmann Institute of Science, Rehovot, Israel.

    • Ilana Rogachev
  5. Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA.

    • Wuzhou Wan
    •  & Philip M Murphy
  6. Department of Embryology, Carnegie Institution for Science, Baltimore, Maryland, USA.

    • Steven A Farber
  7. Department of Genetics, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem, Israel.

    • Liran Carmel
  8. Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

    • Gregory S Shelness

Authors

  1. Search for Inbal Avraham-Davidi in:

  2. Search for Yona Ely in:

  3. Search for Van N Pham in:

  4. Search for Daniel Castranova in:

  5. Search for Moshe Grunspan in:

  6. Search for Guy Malkinson in:

  7. Search for Liron Gibbs-Bar in:

  8. Search for Oded Mayseless in:

  9. Search for Gabriella Allmog in:

  10. Search for Brigid Lo in:

  11. Search for Carmen M Warren in:

  12. Search for Tom T Chen in:

  13. Search for Josette Ungos in:

  14. Search for Kameha Kidd in:

  15. Search for Kenna Shaw in:

  16. Search for Ilana Rogachev in:

  17. Search for Wuzhou Wan in:

  18. Search for Philip M Murphy in:

  19. Search for Steven A Farber in:

  20. Search for Liran Carmel in:

  21. Search for Gregory S Shelness in:

  22. Search for M Luisa Iruela-Arispe in:

  23. Search for Brant M Weinstein in:

  24. Search for Karina Yaniv in:

Contributions

I.A.-D. conducted experiments, data analyses and wrote the manuscript. Y.E., V.N.P., M.G., G.M., L.G.-B. and O.M. performed zebrafish experiments. G.A. managed the fish facility. D.C., B.L., J.U., K.K. and K.S. contributed to the F3 mutagenesis screen. C.M.W. and T.T.C. performed in vitro studies. I.R. performed lipidomics analyses. W.W. and P.M.M. provided the ApoE-null mice. S.A.F. provided advice in lipids studies. L.C. conducted statistical analyses and developed software for quantification. G.S.S. supervised in vitro experiments and provided advice in lipids studies. M.L.I.-A. supervised in vitro studies. B.M.W. supervised the initial zebrafish studies and provided advice throughout the project. K.Y. conducted experiments and data analyses, wrote the manuscript and supervised the project.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Karina Yaniv.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–7

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.2759

Further reading